These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21129061)

  • 21. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
    Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
    Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
    Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-label Inductive Matrix Completion for Joint MGMT and IDH1 Status Prediction for Glioma Patients.
    Chen L; Zhang H; Thung KH; Liu L; Lu J; Wu J; Wang Q; Shen D
    Med Image Comput Comput Assist Interv; 2017 Sep; 10434():450-458. PubMed ID: 29770368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma.
    Wongsurawat T; Jenjaroenpun P; De Loose A; Alkam D; Ussery DW; Nookaew I; Leung YK; Ho SM; Day JD; Rodriguez A
    Acta Neuropathol Commun; 2020 Jun; 8(1):87. PubMed ID: 32563269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
    Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G
    Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
    Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
    Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
    J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Chamberlain MC
    Neurology; 2014 Jun; 82(23):2147-8. PubMed ID: 24912510
    [No Abstract]   [Full Text] [Related]  

  • 32. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population.
    Malueka RG; Dwianingsih EK; Bayuangga HF; Panggabean AS; Argo IW; Donurizki AD; Shaleh S; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2287-2295. PubMed ID: 32856857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress in the application of molecular biomarkers in gliomas.
    Wang J; Su HK; Zhao HF; Chen ZP; To SS
    Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive biomarkers in adult gliomas: the present and the future.
    Thomas L; Di Stefano AL; Ducray F
    Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [
    Cimini A; Chiaravalloti A; Ricci M; Villani V; Vanni G; Schillaci O
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGMT testing--the challenges for biomarker-based glioma treatment.
    Wick W; Weller M; van den Bent M; Sanson M; Weiler M; von Deimling A; Plass C; Hegi M; Platten M; Reifenberger G
    Nat Rev Neurol; 2014 Jul; 10(7):372-85. PubMed ID: 24912512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
    Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
    Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality assurance in neuropathology: Experiences from the round robin trials on
    Riemenschneider MJ; Fischer J; Grassow-Narlik M; Mawrin C; von Deimling A; Pietsch T; Reifenberger G; Mueller WC; Sommer CJ; Dietel M; Zoubaa S; Lorenz J; Rothhammer-Hampl T
    Clin Neuropathol; 2020; 39(5):203-211. PubMed ID: 32352373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.